Comparison of SGLT2 and DPP4 inhibitors on clinical outcomes in chronic obstructive pulmonary disease (COPD) patients with diabetes: A nationwide cohort study
Main finding · Overall COPD exacerbationResult — go to the resultHazard ratio 0.69 95% CI 0.52–0.92Authors' conclusion
SGLT2i use in COPD patients with DM was associated with reduced risks of COPD exacerbation, particularly for severe acute exacerbation compared with DPP4i. This finding suggested that SGLT2i therapy may have a protective effect against severe exacerbations in COPD management.
Study context
- Population
- Patients with COPD and Diabetes Mellitus (DM), Taiwan's National Health Insurance Research Database
- Participants
- 188 vs 181
- Exposure
- SGLT2i vs DPP4i
- SGLT2in = 188
- DPP4in = 181reference
- Outcome
- Risk of COPD exacerbation and mortality
Methodological detailsactive comparator new user design, Cox regression model
- Active comparator new user design
- Cox regression model
Main finding
Overall COPD exacerbation
Hazard ratio
0.69
95% CI 0.52–0.92
SGLT2ivs DPP4i
HR 0.69 (95% CI 0.52–0.92)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Severe acute exacerbations | 0.35 (0.20–0.61) | |
| Mortality | 1.51 (0.53–4.25) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Comparison of SGLT2 and DPP4 inhibitors on clinical outcomes in COPD patients with diabetes: A nationwide cohort study. Diabetes Res Clin Pract. Published 3 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →